Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors

Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors

<b>Background/Objectives:</b> Janus kinase inhibitors (JAKi) have revolutionized the treatment of various inflammatory and immune disorders. Concerns about the potential increased risk of major adverse cardiovascular events (MACEs) associated with JAKi use led to a European Medicines Age...

Full description

Saved in:
Bibliographic Details
Main Authors: Elisabet Castañeda-Estévez, Cristina Vergara-Dangond, Martina Steiner, Maria Beatriz Paredes-Romero, Ana Esteban-Vázquez, Tatiana Cobo-Ibañez, Laura Trives-Folguera, Maria Liz Romero-Bogado, Isabel De La Cámara-Fernández, Patricia Richi-Alberti, Ana Acosta-Alfaro, Iría De la Osa-Subtil, Santiago Muñoz-Fernández
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceuticals
Subjects:
JAK inhibitors
cardiovascular risk
health alert
Online Access:https://www.mdpi.com/1424-8247/18/1/22
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/1/22

Similar Items